Two things need separating during a transition. Nausea, reduced appetite and a stalled weight trajectory are the ordinary signature of a restarted escalation. Severe abdominal pain, persistent vomiting with dehydration, a neck lump, or hoarseness that will not clear are on both labels as reactions requiring attention rather than patience.
The escalation phase is where symptoms concentrate
Both prescribing information documents tie their titration schedules explicitly to reducing gastrointestinal adverse reactions, which is a statement about when those reactions cluster. A switch puts a person back into that window after they had left it, which is why symptoms that had settled months earlier reappear.
The tirzepatide labeling quantifies the severe end. Pooled across two weight reduction trials, severe gastrointestinal adverse reactions occurred in 1.7 percent of patients at 5 mg, 2.5 percent at 10 mg and 3.1 percent at 15 mg, compared with 1 percent on placebo. Discontinuation because of adverse reactions ran at 4.8, 6.3 and 6.7 percent across those doses against 3.4 percent on placebo, mostly during escalation. Severe is a small minority. Uncomfortable is common.
Knowing which symptoms belong to which drug is easier when the two labels are summarized side by side, and telehealth companies vary in how plainly they do that. Hims and Hers, Henry Meds and Sesame frame their own programs, while HealthRX maintains a Wegovy vs Zepbound overview that sets the shared gastrointestinal profile and the separate warnings against each other. A page that treats the two as distinct molecules with overlapping effects is better preparation for a switch than one selling a single product.
What is expected and what is not
| What is observed | How it usually reads |
|---|---|
| Nausea in the days after an increase, easing before the next one | Ordinary escalation effect described in both labels |
| Appetite suppression weaker than at the previous maintenance dose | Expected, since an initiation dose is lower in its own range |
| Weight flat or slightly up during early transition weeks | A consequence of reduced exposure, not a treatment failure |
| Vomiting or diarrhea severe enough to stop fluid intake | Volume depletion risk, linked in the labeling to acute kidney injury |
| Severe, persistent abdominal pain, with or without vomiting | Both labels direct discontinuation if pancreatitis is suspected |
| Right upper abdominal pain, fever, jaundice | Acute gallbladder disease appears in both labels |
| Neck mass, difficulty swallowing, breathlessness, persistent hoarseness | Symptoms named in the boxed warning on both products |
| Swelling of the face or throat, rash with breathing difficulty | Serious hypersensitivity, including anaphylaxis and angioedema |
The boxed warning applies to both molecules
Semaglutide caused dose-dependent and duration-dependent thyroid C-cell tumors in rodents, and tirzepatide caused them in rats, at clinically relevant exposures. Whether either causes thyroid C-cell tumors including medullary thyroid carcinoma in humans has not been determined. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Both labels also state that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection in treated patients. That is worth knowing before requesting either test as reassurance during a switch. The screening that matters is the family history question, and it is asked again for the new product rather than inherited from the old one.
Warnings that sit outside the digestive tract
Acute kidney injury has been reported after GLP-1 receptor agonist treatment, in some cases requiring hemodialysis, mostly in patients whose gastrointestinal symptoms led to dehydration. Both labels direct monitoring of renal function in patients reporting reactions that could cause volume depletion, and the tirzepatide labeling names dosage initiation and escalation as the period of particular attention. During a switch that period has just restarted.
Hypoglycemia is the other one that arrives through a side door. Both labels flag increased risk when the drug is combined with insulin or an insulin secretagogue, and both may require those doses to be reduced. The semaglutide labeling directs blood glucose monitoring before and during treatment in patients with diabetes. Anyone on those medications whose exposure to appetite suppression drops during a transition and then climbs again is on a moving target.
Two more appear on the semaglutide side and are easy to miss: heart rate increase, and diabetic retinopathy complications in patients with type 2 diabetes. Both labels also carry a warning about pulmonary aspiration during general anesthesia or deep sedation, which is a reason any planned procedure needs the medication disclosed to the anesthesia team.
What is actually worth recording
A transition generates a lot of impressions and very little data unless someone writes it down. The record that helps a prescriber is short: the dose and the date of each step, which symptoms appeared in which days after which increase, weight measured on a consistent schedule rather than daily, and any day where fluids could not be kept down.
That last item is the one people leave out, because it feels like a bad day rather than a clinical event. It is the item most directly connected to the kidney warning in both labels.
Continuity of who reads that record matters as much as keeping it. A practice with the chart can see a pattern across both products, while a service that changes the reviewing clinician at every visit sees a series of unconnected reports. Manufacturer channels such as LillyDirect and NovoCare Pharmacy dispense one company’s branded products, telehealth prescribers including Ro, LifeMD, Sesame and FormBlends each publish their own supervision model and pricing, and asking who reviews a symptom report and how quickly is a fairer test of a service than its monthly headline figure.
Compounded preparations shift the monitoring picture
A pharmacovigilance study of FDA adverse event reports from 2018 to 2024 identified 707 reports involving compounded GLP-1 receptor agonists among 81,078 reports overall. Compounded products showed higher reporting odds for abdominal pain, diarrhea, nausea and cholecystitis, considerably higher odds of preparation errors and contamination, and roughly double the odds of hospitalization. The authors note the analysis was not designed to establish cause and effect.
Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before dispensing. Where either side of a transition involves one, the clinician needs to know the exact product and pharmacy in order to interpret a symptom at all.
Frequently asked questions
Is nausea after switching a warning sign?
Usually not on its own. Mild to moderate nausea clustering after a dose increase and easing before the next is the documented pattern in both trial programs. Nausea with persistent vomiting, an inability to keep fluids down, or severe abdominal pain is a different report and needs prompt review.
Should weight regain during the transition be treated as failure?
No. Dropping from a settled maintenance dose to an initiation dose reduces drug exposure, and a flat or slightly rising trajectory follows from that. Assessment belongs at a maintenance dose on the new product, which takes months of titration to reach.
Do thyroid blood tests or scans give reassurance?
Both labels state that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection in treated patients. The relevant safeguard is the contraindication itself, based on personal and family history, plus reporting the symptoms named in the boxed warning.
Does an upcoming operation need to be mentioned?
Yes. Both labels carry a warning about pulmonary aspiration during general anesthesia or deep sedation. The anesthesia team needs to know the drug, the dose and the date of the last injection, and a transition means two products may be relevant to that history.
What about heart rate?
Heart rate increase appears among the warnings on the semaglutide label. Anyone tracking pulse should carry those readings across the transition rather than starting fresh, since a change is easier to interpret against a baseline than against nothing.
